Dont take extra to make up for a missed dose
Your doctor may slow the increase if you have side effects
Patients achieving a 5% reduction from baseline in body weight was a co-primary outcome in the STEP 1 to STEP 3 studies, and there were greater percentages of patients in the semaglutide group than in the placebo group who achieved a 5% weight loss by week 68 in each of STEP 1 (odds ratio [OR] = 11.22 [95% CI, 8.88 to 14.19
Additional costspharmacy consultation fees, telehealth provider visits, or genetic testingvary by practice model
ALLEGORY is now the third positive Phase III trial for Gazyva/Gazyvaro in immune-mediated diseases (alongside REGENCY in lupus nephritis and INShore in idiopathic nephrotic syndrome), reinforcing its potential as a transformative therapy in autoimmune and immunologic diseases
ORCID: Marta Mudd: Jeffrey Rado: References (16) Smits MM, van Raalte DH, Tonneijck L, et al